Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
1. A compound according to the chemical structure:
Where Y is a —(CH 2 ) n Z-group wherein n is 4, Z is a NR group and R is H and which group, links the nitrogen of said NR group to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid (DOTA) group X, wherein said DOTA group X incorporates or complexes with a radioisotope selected from the group consisting of 90 Y, 111 In, 177 Lu, 67 Ga, 68 Ga, 209 Bi and 213 Bi, or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 wherein said radioisotope is 90 Y, 213 Bi, 177 Lu or 111 In.
3. The compound according to claim 1 wherein said radioisotope is 213 Bi, 177 Lu, or 111 In.
4. The compound. according to claim 1 wherein said radioisotope is 213 Bi or 177 Lu.
5. The compound according to claim 1 wherein said radioisotope is 213 Bi or 90 Y.
6. The compound according to claim 1 which is
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1 and 2 - 6 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
8. The compound according to claim 1 wherein said radioisotope is 90 Y, 209 Bi or 213 Bi.
9. The compound according to claim 1 wherein said radioisotope is 90 Y or 209 Bi.
10. The compound according to claim 1 wherein said radioisotope is 90 Y.
11. The compound according to claim 1 wherein said radioisotope is 209 Bi.
12. The compound according to claim 1 wherein said radioisotope is 177 Lu or 111 In.
13. The compound according to claim 1 wherein said radioisotope is 177 Lu.
14. The compound according to claim 1 wherein said radioisotope is 111 In.
15. The compound according to claim 1 wherein said radioisotope is 67 Ga or 68 Ga.
16. The compound according to claim 15 wherein said radioisotope is 67 Ga.
17. The compound according to claim 15 wherein said radioisotope is 68 Ga.